The melanocortin-1 receptor (MC1R), a G-protein-coupled receptor, has a crucial role in human and mouse pigmentation [1] [2] [3] [4] [5] [6] [7] [8] . Activation of MC1R in melanocytes by α-melanocyte-stimulating hormone (α-MSH) 9 stimulates cAMP signalling and melanin production and enhances DNA repair after ultraviolet irradiation [10] [11] [12] [13] [14] [15] [16] . Individuals carrying MC1R variants, especially those associated with red hair colour, fair skin and poor tanning ability (denoted as RHC variants), are associated with higher risk of melanoma 5,17-20 . However, how MC1R activity is modulated by ultraviolet irradiation, why individuals with red hair are more prone to developing melanoma, and whether the activity of RHC variants might be restored for therapeutic benefit are unknown. Here we demonstrate a potential MC1R-targeted intervention strategy in mice to rescue loss-offunction MC1R in MC1R RHC variants for therapeutic benefit by activating MC1R protein palmitoylation. MC1R palmitoylation, primarily mediated by the protein-acyl transferase ZDHHC13, is essential for activating MC1R signalling, which triggers increased pigmentation, ultraviolet-B-induced G1-like cell cycle arrest and control of senescence and melanomagenesis in vitro and in vivo.
), before being treated with medium containing BSA-conjugated fatty acids for 3 h. Palmitic acid, but not other lipids, increased cAMP levels in both HPM-RHC and B16-RHC cells (Fig. 1a, Extended Data Fig. 1a) .
As palmitic acid can induce palmitoylation of cysteine residues (Extended Data Fig. 1b) , we treated cells with the general palmitoylation inhibitor 2-bromopalmitate. 2-bromopalmitate prevented palmitic acid-induced cAMP levels in both HPM-RHC and B16-RHC cells (Fig. 1b, Extended Data Fig. 1c ), as well as in wild-type B16 cells and HPMs, with the effect of palmitic acid being dependent on α -MSH and stimulated by ultraviolet irradiation (UVR; Extended Data Fig. 1d, e) . Using an acyl-biotin exchange (ABE) assay in HPM-RHC cells (Extended Data Fig. 1f ), free cysteine thiol groups were irreversibly blocked by N-ethylmaleimide, palmitoylated cysteines exposed by hydroxylamine and biotinylated. Labelled proteins pulled down using streptavidin-coupled Dynabeads were analysed by mass spectrometry (Extended Data Fig. 1g ) to reveal that MC1R is palmitoylated (Extended Data Fig. 1h ), consistent with G-protein-coupled receptors such as MC1R 9 being palmitoylated during activation. Palmitoylation site prediction analysis 21 highlighted MC1R cysteines 78 and 315 as potential palmitoylation sites (Extended Data Fig. 1i-k) .
Palmitoylation of both endogenous MC1R and exogenously expressed Flag-MC1R was confirmed using streptavidin to detect MC1R protein labelled using ABE, following immunoprecipitation from B16 cells and HPMs stimulated with α -MSH (Fig. 1c, d , Extended Data Fig. 2a, b) . The Flag-MC1R(C78S) mutant, but not Flag-MC1R(C315S), was also palmitoylated (Fig. 1e , Extended Data Fig. 2c ), indicating that C315 is the major MC1R palmitoylation site.
Using MC1R-reconstituted cells, we showed that, in the presence of α -MSH, both R151C and R160W MC1R variants exhibited reduced palmitoylation compared to wild type (Fig. 1f , Extended Data Fig. 2d ). Moreover, a C315S mutation in the context of the R151C variant completely blocked MC1R(R151C) palmitoylation, indicating that Cys151 is not a neo-palmitoylation site (Extended Data Fig. 2e, f) . Notably, UVR stimulated palmitoylation of endogenous MC1R and exogenously expressed Flag-MC1R (Fig. 1g , h, Extended Data Fig. 2g, h ), but not the MC1R(C315S) mutant (Fig. 1i, Extended Data Fig. 2i ), whereas UVR-induced palmitoylation of the R151C and R160W RHC variants was reduced compared to the wild-type protein (Fig. 1j , k, Extended Data Fig. 2j-m) .
To identify which protein S-acyl transferases were responsible for MC1R modification, 23 haemagglutinin (HA)-tagged ZDHHC protein S-acyl transferases 22 were co-expressed with Flag-MC1R. Detectable MC1R palmitoylation was only observed following expression of ZDHHC2, 3, 7, 13 and 17 (Extended Data Fig. 3a) , with ZDHHC13 being the most efficient (Fig. 2a) . MC1R palmitoylation was substantially reduced in cells expressing a C456S mutant form of ZDHHC13 in which the enzymatic DQHC motif was mutated (Fig. 2b , Extended Data Fig. 3b ). Silencing ZDHHC13 diminished UVR-stimulated palmitoylation of wild-type MC1R (Fig. 2c, Extended Data Fig. 3c ), as well as the R151C RHC variant (Fig. 2d, Extended Data Fig. 3d ), whereas ZDHHC13 overexpression activated MC1R(R151C) palmitoylation (Fig. 2d , Extended Data Fig. 3d-f ). The MC1R(C315S) mutant was used as a negative control.
Interaction between ZDHHC13 and MC1R was detected by co-immunoprecipitation from α -MSH-treated HPMs and was enhanced by UVR ( following UVR (Extended Data Fig. 3g, h ). Interaction between the MC1R RHC R151C and R160W proteins and ZDHHC13 was also increased after UVR, but less so than observed with wild-type MC1R (Fig. 2f) .
As ATR is a central effector of the UVB response 23, 24 , we investigated whether ATR-mediated phosphorylation of ZDHHC13 promoted MC1R palmitoylation following exposure to ultraviolet light. HPMs expressing HA-ZDHHC13 were irradiated with UVB, and after anti-HA immunoprecipitation, phosphorylation of ZDHHC13 was detected by specific phospho-SQ/TQ antibody. The results revealed that UVB treatment increased ZDHHC13 phosphorylation (Fig. 2g ) and MC1R-ZDHHC13 interaction (Fig. 2h ) that was substantially reduced in cells stably expressing ATR-targeting shRNA (Fig. 2i) . Mutation of an evolutionarily conserved SQ site at Ser8 (Extended Data Fig. 3i ) prevented UVR-stimulated ZDHHC13 phosphorylation (Extended Data Fig. 3j ) and wild-type ATR, but not a kinase-dead mutant, robustly phosphorylated recombinant wild-type ZDHHC13, but not the S8A mutant (Extended Data Fig. 3k ). Compared to wild-type ZDHHC13, the S8A mutant only weakly interacted with MC1R (Extended Data Fig. 3l ) and failed to enhance MC1R palmitoylation upon UVB irradiation (Extended Data Fig. 3m ). Collectively, these results suggest that ZDHHC13 phosphorylation by ATR following UVB irradiation promotes its interaction with MC1R to stimulate palmitoylation of MC1R.
To test whether MC1R palmitoylation regulates MC1R signalling [10] [11] [12] [13] [14] [15] [16] cAMP levels were measured after UVB irradiation and α -MSH stimulation of MC1R-reconstituted cells. Whereas wild-type MC1R significantly increased cAMP levels following UVR, the palmitoylation-deficient mutant C315S failed to do so, and RHC variants partially lost the ability to stimulate cAMP production (Extended Data Fig. 4a ). The C315S mutant also failed to upregulate microphthalmia-associated transcription factor (Mitf) and tyrosinase (Tyr) mRNA expression (Extended Data Fig. 4b , c) downstream of MC1R signalling. The MC1R RHC variants only weakly activated MITF and TYR expression compared to wild type, strongly suggesting that palmitoylation is essential for MC1R signalling.
To examine the role of MC1R palmitoylation in α -MSH-MC1R-regulated DNA repair, endogenous MC1R-reconstituted HPMs, cyclobutane pyrimidine dimer (CPDs) and 6-4 photoproducts were measured following UVB exposure. Although wild-type MC1R promoted clearance of CPDs and 6-4 photoproducts, the palmitoylationdefective C315S mutant and the RHC variants failed to repair the lesions efficiently (Extended Data Fig. 4d ).
Consistent with previous work 25 , silencing MC1R augmented low-dose UVB-induced premature senescence that was bypassed by reintroduction of wild-type MC1R (Extended Data Fig. 4e ). The R151C and R160W RHC variants also exhibited a defective senescence bypass phenotype, whereas the C315S mutant was ineffective (Extended Data Fig. 4f ). Using engineered human immortal melanocytes (hTERT/ p53DD/CDK4(R24C) melanocytes) 25, 26 in colony formation and soft agar growth assays we found that BRAF(V600E)-mediated cellular transformation was suppressed by wild-type MC1R, but not the C315S mutant, whereas the R151C and R160W variants exhibited an intermediate phenotype (Fig. 3a, Extended Data Fig. 4g-k) .
To examine its role in cAMP production, ZDHHC13 was silenced or overexpressed in MC1R-reconstituted B16 cells and HPMs, and cAMP were levels measured following UVB irradiation and stimulation with α -MSH. ZDHHC13 overexpression increased cAMP levels in cells expressing wild-type MC1R and also rescued the defect in cAMP production in cells expressing the R151C variant (Extended Data Fig. 5a ). ZDHHC13 overexpression increased MITF expression in wild-type cells and rescued the defect in α -MSH and MC1R RHC-variant-induced MITF upregulation (Extended Data Fig. 5b ).
The palmitoylation-defective C315S mutant was inactive irrespective of ZDHHC13 expression. ZDHHC13 overexpression enhanced UVRinduced DNA damage repair and rescued the defect in clearance of 6-4 photoproducts in melanocytes with the MC1R(R151C) variant, whereas ZDHHC13 depletion reduced repair (Extended Data Fig. 5c ). Similarly, ZDHHC13 overexpression protected against UVB-induced premature senescence in melanocytes expressing wild-type and MC1R(R151C), but not those expressing the C315S mutant, whereas shRNA depletion of ZDHHC13 enhanced senescence in cells expressing wild-type or MC1R(R151C) (Extended Data Fig. 5d ).
Soft agar and colony formation assays using the human hTERT/ p53DD/CDK4(R24C) melanocytes 25, 26 revealed that ZDHHC13 depletion increased transformation by BRAF(V600E) in the presence of wild-type MC1R, whereas enhanced transformation by the R151C mutant was suppressed by ZDHHC13 overexpression (Fig. 3b,  Extended Data Fig. 5e ). Elevated transformation in the presence of the C315S mutant was unaffected by ZDHHC13 overexpression/depletion. Subcutaneous xenograft tumour assays also indicated that ZDHHC13 overexpression inhibits MC1R(R151C)-augmented BRAF(V600E)-induced malignant transformation (Fig. 3c-e) .
We next used MC1R loss-of-function (C57BL/6J-Mc1r e/e J) mice, backcrossed to C57BL/6 for more than 24 generations, to generate transgenic mice re-expressing melanocyte-specific wild-type, RHCvariant and C315S-mutant MC1R (Extended Data Fig. 6a ). Unlike previous transgenic MC1R RHC mice developed by Healy et al. 3 using bacterial artificial chromosomes, our Mc1r R151C variant offspring show a mosaic coat colour that could arise as a consequence of the promoter used, the integration site or the mouse strain background. Our other RHC variants exhibited a paler coat colour than the wild type (Fig. 4a,  Extended Data Fig. 6b ). All mice are at generation F26 or later with stable fur phenotypes and exhibit similar expression levels of the human transgenic Mc1r mRNAs (Extended Data Fig. 6c ). The MC1R(R151C) variant mice also exhibit higher skin pheomelanin/eumelanin ratios than wild-type mice (Fig. 4b) . Notably, the palmitoylation-deficient MC1R(C315S)-expressing mice had a similar coat colour and skin Fig. 5f ), melanomas developed early and frequently in MC1R loss-of-function (e/e) or palmitoylation-defective MC1R transgenic (C315S) mice, much later with wild-type MC1R mice, and at an intermediate time with the MC1R(R151C) variant (Fig. 4c) . All of the diagnosed melanomas displayed similar morphological and histologic features (Extended Data Fig. 6g ).
To explore whether MC1R palmitoylation is dynamic, we removed α -MSH from the culture medium and found that palmitoylation disappeared within 12 h, whereas addition of palmostatin B (Palm-B), a deacylating enzyme inhibitor 28, 29 , blocked both wild-type and MC1R(R151C) depalmitoylation (Extended Data Fig. 7a ), suggesting that Palm-B enhances MC1R palmitoylation. Treatment of endogenous MC1R reconstituted B16 cells with Palm-B, together with α -MSH and UVB irradiation, increased MC1R(R151C) palmitoylation to levels detected for the wild-type protein, whereas no palmitoylation was observed using the C315S mutant irrespective of Palm-B administration (Extended Data Fig. 7b) . Using HPMs or B16 cells reconstituted with wild-type or variant MC1R, we found that Palm-B moderately increased α -MSH-induced cAMP production, but markedly increased signalling C315S , n = 20. By log-rank test, P = 0.0001 (e/e, + /+ ), P = 0.0179 (e/e, R151C), P = 0.8943 (e/e, C315S), P = 0.0232 (+ /+ , R151C), P = 0.0001 (+ /+ , C315S), P = 0.0233 (R151C, from the R151C variant to levels comparable to those observed from α -MSH-stimulated wild-type MC1R in the absence of Palm-B (Extended Data Fig. 7c ). Signalling downstream of the R151C variant, as well as wild-type MC1R, was functional as both Mitf and Tyr mRNA expression were upregulated by Palm-B (Extended Data Fig. 7d, e) . Palm-B also accelerated clearance of UVR-induced 6-4 photoproducts in melanocytes with the MC1R(R151C) variant (Extended Data Fig. 7f) . By performing ABE on extracts from mouse skin irradiated with UVB, we confirmed that Palm-B administration to mice increased MC1R palmitoylation in Mc1r R151C and Mc1r +/+ in vivo (Extended Data  Fig. 7g) . Following UVB treatment, both CPD and 6-4 photoproduct DNA lesions were significantly higher in R151C mice than in wildtype mice, with Palm-B reducing the levels of damage detected in both (Extended Data Fig. 7h, i) . Notably, Palm-B also repressed low-dose UVB-induced premature senescence in HPMs or B16 cells reconstituted with the MC1R(R151C) variant (Extended Data Fig. 7j) . In human immortal hTERT/p53DD/CDK4(R24C) melanocytes, Palm-B largely reversed the increased colony formation observed using the R151C variant (Fig. 4d, Extended Data Fig. 7k ) and in xenograft studies, Palm-B inhibited MC1R(R151C)-augmented BRAF(V600E) melanomagenesis (Fig. 4e-g ). Importantly, Palm-B had no effect in any assay using the C315S mutant.
Finally, to confirm the preventive effect of Palm-B in melanomagenesis, the transgenic mice re-expressing melanocyte-specific MC1R(R151C) (Tyr-Cre-BRAF
CA -Mc1r
e/e Mc1r R151C ) were UVBirradiated each week for four weeks, with 10 mg per kg body weight Palm-B injected intraperitoneally before irradiation. Although no strong side effects were observed, in Palm-B-treated mice melanomagenesis was substantially delayed and the incidences reduced (Fig. 4h) . Similar results were obtained using Palm-B and the MC1R(R160W) variant (Extended Data Fig. 8) .
Collectively, our results highlight a central role for MC1R palmitoylation in protecting against melanoma, and suggest that rescuing MC1R palmitoylation by upregulation of ZDHHC13 or inhibition of depalmitoylation might be a potential clinical prevention strategy for melanoma in individuals carrying red hair colour variants.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
Letter reSeArCH

MethOdS
Data reporting. Sample sizes were determined based on previous model-specific experience and no statistical methods were used to predetermine sample size. Mice were randomly assigned to treatment groups. The investigators were blinded to allocation during experiments and outcome assessment whenever possible. Cell lines, animals and UV exposure. Cell lines and ultraviolet (UV) exposure were as described previously 2, 25, 30 . B16 and HEK293 cell lines were purchased from ATCC, authenticated by ATCC, and mycoplasma negative. Briefly, cells were washed by PBS twice before UVB irradiation. For the in vitro UV experiments, cells were exposed to ultraviolet radiation in the Stratalinker UV chamber (Stratagene) with UVB bulbs (UVP LLC). UV emittance was measured with the use of a UV photometer (UVP LLC) 30 . Adherent cells were irradiated through a small volume of PBS at a dose of 100 J m −2 . A UVB dose of 100 J m −2 is equivalent to one standard erythema dose of UVB (SED), commonly used as a measurement of sunlight. As a reference, the ambient exposure over an entire sunny summer day in Europe (Switzerland) is approximately 30-40 SED 31 . Human primary melanocytes were isolated from normal discarded foreskins as described before 32,33 and were cultured in Medium 254 (Thermo Fisher Scientific Inc.). In all assays, cells were pretreated with α -MSH (1 μ M) for 30 min following with 100 J m −2 UVB irradiation, and collected 3 h after UVB exposure. Palm B was used at 1 μ M.
The maximal tumour size is 20 mm at the largest diameter, which was permitted by IACUC of Boston University Medical Campus. None of the experiments exceeded the limit. Mice were maintained in a specific-pathogen-free facility of the Animal Science Center (ASC) of Boston University Medical Campus, and the experiments were performed according to the Institutional Animal Care and Use Committee of Boston University Medical Campus. Mice were housed on a time cycle of 12 h of light (beginning at 6:00) and 12 h of dark (beginning at 18:00). Mice were allowed free access to an irradiated diet and sterilized water. The mice were monitored daily for signs of health status and distress. Mice aged from 8 weeks to 6 months were used for breeding and pregnant females were placed in a new cage. Mice were weaned at 20-21 days of age. DNA was extracted from the mouse tail biopsy for genotyping. NCr nude mice (female, 8-10 weeks) were purchased from Taconic Biosciences. C57BL/6J-Mc1r Transgenic mice were designed to express melanocyte-specific MC1R RHCvariant (controlled by the Tyr enhancer/promoter) and generated by Boston University School of Medicine Transgenic and Genome Engineering Core. The expression construct was designed such that the MC1R gene was inserted downstream of the murine tyrosinase locus control region. Each construct was injected into single-cell embryos of C57BL/6J-Mc1r e/e J mice. The transgene was detected by genotyping mice tail DNA using the primers targeting fragment across Tyr promoter and MC1R region (~ 1,200 bp, forward 5′ -GGGCTATGTACAAACTCCAAGA-3′ , reverse 5′ -ACACTTAAAGCGCGTGCACCGC-3′ ). The expression levels of human transgene were determined as described 3 . Briefly, total RNA was collected from primary melanocytes isolated from neonatal transgenic mouse skins using RNeasy Mini Kit (Qiagen, Hilden, Germany). A sequential DNA remove was performed by DNA-free DNA Removal Kit (Thermo Fisher Scientific Inc.) to avoid genomic DNA contamination. Reverse transcription was carried out with random primers. Primers were used as previously described 7 to amplify both the mouse and human MC1R. A following extension was performed using primer as previously described 3 by adding ddTTP (mouse MC1R) or ddCTP (human MC1R) (SNaPshot Multiplex Kit, Thermo Fisher Scientific Inc.). Extension products were separated by capillary electrophoresis and quantified by measuring the human/mouse MC1R ratio. Mice underwent tamoxifen treatment to express BRAF(V600E) in melanocytes. Briefly, mice at 3 weeks of age were administered with tamoxifen (T5648) (Sigma-Aldrich) in corn oil daily by intraperitoneal injection at 0.12 mg per g body weight for 5 consecutive days. The control mice received a plain corn oil injection. Mouse UV exposure procedure was performed as described previously 30 . Briefly, a UVB dose of 500 J m −2 was used. This dose is equivalent to one minimum erythema dose of UVB (MED) and 5 standard erythema doses of UVB (SED), commonly used as a measurement of sunlight in vivo. Plasmid, transfection, lentiviral and retroviral infections. 23 HA-tagged ZDHHC family protein-encoding plasmids were provided by X. Wu with the permission of M. Fukata 22 . pcDNA3-Flag-MC1R wild-type and RHC variants R151C, R160W and D294H were generated as previously described 25 . To generate the MC1R or ZDHHC13 expression plasmids for retroviral infection, the cDNAs were subcloned into pQCXIP (Clonetech) at the NotI/EcoRI sites, respectively. All other mutants were generated by site-directed mutagenesis using the QuickChange II Site-Directed Mutagenesis kit (Agilent). To generate stable knockdown of MC1R or ZDHHC13 in B16 and HPMs, mouse or human specific short hairpin RNAs in pLKO.1 against MC1R or ZDHHC13 were co-transfected with psPAX2 (Addgene #12260) and pMD2.G (Addgene, #12259) in HEK293-FT (ATCC) using Lipofectamine 3000 (Thermo Fisher Scientific Inc.). Lentiviruses were collected after 48 h, and then infected cells for 24 h in the presence of polybrene (8 μ g ml
) and the infected cells were selected with puromycine (2 μ g ml −1 ). To generate cells with stable expression of MC1R variants or HA-ZDHHC13, HEK293T cells were co-transfected with MC1R variants or HA-ZDHHC13 in pQCXIP, VSV-G and pUMVC (Addgene, #8449) plasmids using Lipofectamine 3000. Retroviruses were harvested after 48 h and cells were infected with retroviruses in the presence of polybrene (8 μ g ml −1 ). After 24 h, cells were selected with puromycine (2 μ g ml −1 ). shRNA constructs targeting human MC1R (RHS4533-EG4157), mouse MC1R (RMM4534-EG17199), human ZDHHC13 (RHS4533-EG54503), mouse ZDHHC13 (RMM4534-EG243983) and human ATR (RHS4533-EG545) were purchased from OpenBiosystems. The most efficient knockdown cell lines with shmMC1R (target sequence: 5′ -AATGGAGATCAGGAAGGGATG-3′ ) or shMC1R (target sequence: 5′ -AAATGTCTCTTTAGGAGCCTG-3′ ) were used in assays. pcDNA3-ATR wild-type (Addgene, #31611) and pcDNA3-ATR Kinase dead (Addgene, #31612) were gifts from A. Sancar 34 . Immunoblot analysis. High Sensitivity Streptavidin-HRP (21130) and Dynabeads MyOne Streptavidin C1 (65001) were purchased from Thermo Fisher Scientific Inc. Anti-ZDHHC13 antibody (ab28759) was purchased from Abcam. Anti-MC1R antibody (N-19) (sc-6875) was purchased from Santa Cruz Biotechnologies, Inc. Monoclonal anti-β -actin− peroxidase antibody (AC15), monoclonal anti-Flag M2-peroxidase antibody (A8592), monoclonal anti-HAperoxidase antibody (H6533), anti-Flag agarose beads (A2220), anti-HA agarose beads (A2095), peroxidase-conjugated anti-mouse secondary antibody (A4416) and peroxidase-conjugated anti-rabbit secondary antibody (A-4914) were purchased from Sigma-Aldrich. All western blots shown are representatives of three independent experiments. Co-immunoprecipitation. Briefly, cells were washed twice with ice-cold phosphate-buffered saline and lysed in lysis buffer containing 50 mM Tris pH 7.4; 1% Triton X-100; 0.5 mM EDTA; 0.5 mM EGTA; 150 mM NaCl; 10% glycerol; 1 mM phenylmethylsulfonyl fluoride, complete protease inhibitor cocktail (Roche) on ice for 30 min. The supernatant was collected after centrifugation at 15,000g for 15 min at 4 °C, and 500 μ g of total cell lysate was treated by DNase (15 U ml −1 , Pierce), precleared by 20 μ l Protein G Agarose Beads (Thermo Fisher Scientific Inc.) and then incubated with primary antibodies overnight at 4 °C or Flag/HA beads (Sigma-Aldrich) directly for 2 h. 20 μ l of Protein G Agarose Beads was added into the samples with rotation at 4 °C for 1 h. After three washes with 1 ml of lysis buffer, the bound proteins were released by boiling in 30 μ l of SDS loading buffer and detected as described above. Acyl-biotin exchange palmitoylation assay. Briefly, cells were lysed by lysis buffer (1% IGEPAL CA-630, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl 10% glycerol and protease inhibitor) with 50 mM N-ethylmaleimide (Sigma-Aldrich) and endogenous MC1R or Flag-MC1R was then purified by specific antibodies and beads. Purified MC1R protein was divided into two groups, and one treated with lysis buffer + 1 M hydroxylamine (Sigma-Aldrich) for 1 h at room temperature. Finally, the beads were gently washed with lysis buffer pH 6.2 and incubated with lysis buffer pH 6.2 + 2 μ M biotin-BMCC (Thermo Fisher Scientific Inc.) for 1 h at 4 °C. Proteins were washed three times and used for immunoblot analysis. Mass spectrometry. Mass spectrometry protein identification was performed by the Taplin Biological Mass Spectrometry Facility, Harvard Medical School. Protein samples were mixed with sample buffer and heated at 100 °C for 5 min, then loaded to SDS-PAGE for separation. When running was finished, gel was immersed within staining solution (0.3% Coomassie blue, 45% methanol, 10% glacial acetic acid and 45% dH 2 O) and placed on a shaker for 30 min. Gel was de-stained in destaining solution (20% methanol, 10% glacial acetic acid, 70% dH 2 O) on the shaker overnight. Finally, bands on the gel were excised and sent to the Taplin Biological Mass Spectrometry Facility for mass spectrometry protein identification. Immunoassay. DNA damage immunoassay was performed using the anti-CPD (MC-062) and anti-6-4-photoproducts (KTM-50) antibodies. Briefly, the heatdenatured genomic DNA were coated onto the microplate wells with Pierce DNA Coating Solution (17250) (Thermo Fisher Scientific Inc). After washing and blocking by PBS with the purified anti-mouse IgG mAb of 2 μ g ml −1 , the specific antibodies of anti-CPD (MC-062) and anti-6-4-photoproducts (KTM-50) were diluted 1:1,000 in blocking buffer and added to each well. Optical density at 405 nm was determined. Intracellular cAMP levels were measured by cAMP Direct Immunoassay Kit (ab65355) (Abcam) following the manufacture's protocol, optical density at 450 nm was determined. For cAMP measurement with fatty acid treatment, fatty acids were dissolved in 100% ethanol (250 mM) mixed with 25 mM BSA and added to serum-free DMEM/medium 254 at a final concentration of 500 μ M. Cells were serum-starved for 6 h. For the last 30 min, cells were incubated with 1 μ M α -MSH, followed by 100 J m −2 UVB treatment. Lastly cells were treated with indicated BSA-conjugated fatty acid medium for 3 h with or without 2-BP (25 μ M). All results are calculated by three independent experiments. Quantitative PCR. The cDNA (40 ng) was used for quantitative PCR amplification with SYBR green PCR master mix (Thermo Fisher Scientific Inc.). The relative levels of expression of genes were normalized according to those of GAPDH. Quantitative PCR (qPCR data were calculated using the comparative C t method. All quantitative PCR were performed in triplicate, and three independent RNA samples were assayed for each time point. All primers are listed and purchased from Integrated DNA Technologies (Coralville). Mouse Mitf forward, 5′-GCCTGAAACCTTGCTATGCTGGAA-3′ , reverse, 5′-AAGGTACTGCTTTACCTGGTGCCT-3′ ; human MITF forward, 5′-CGAGCTCATGGACTTTCCCTTA-3′ ; reverse, 5′-CTTGATGATCCGAT TCACCAAA-3′ ; mouse Tyr forward, 5′-ATTGATTTTGCCCATGAAGC-3′ , reverse, 5′-CCCAGATCCTTGGATGTTATG-3′ ; human TYR forward, 5′-AGCAC CCCACAAATCCTAACTTAC-3′ , reverse, 5′-ATGGCTGTTGTACTCCTC CAATC-3′ ; mouse Gapdh forward, 5′-CCCATCACCATCTTCCAGGAGC-3′ , reverse, 5′-CCAGTGAGCTTCCCGTTCAGC-3′ ; human GAPDH forward, 5′-ACCCACTCCTCCACCTTTGA-3′ , reverse, 5′-CTGTTGCTGTAGCCAA ATTCGT-3′ . All results are calculated by three independent experiments. Immunohistochemistry. Mouse melanomas were fixed in 10% formalin solution at 4 °C overnight, paraffin-embedded and then cut into 5-μ m-thick sections (Dermpath core facility, Boston University). Sections were then deparaffinized, rehydrated, and stained with anti-S-100 (Dako North America, Inc.) and counterstained with haematoxylin. Briefly, for antigen retrieval, sections were heated in a boiling water bath in 10 mM sodium citrate buffer (pH 6.0) for 20 min before immunostaining. Nonspecific staining was blocked by pre-incubation with Tris buffered saline (TBS)/0.1% Tween-20/5% normal goat serum (Jackson ImmunoResearch) for 1 h at room temperature. Tissue sections were incubated with the primary antibodies at 4 °C overnight, and were subsequently incubated with secondary antibodies and detected with DAB substrate (Dako EnVision + System HRP, Dako) following manufacturer's instructions. Coverslips were mounted onto glass slides with permanent mounting medium. All images were taken with an Olympus Inverted microscope (Cellular imaging core, Boston University). Pigment measurement. Eumelanin were and pheomelanin were quantified by HPLC based on the level of pyrrole-2,3,5-tricarboxylic acid (PTCA) by alkaline hydrogen peroxide oxidation of eumelanin and 4-amino-3-hydroxyphenylalanine (4-AHP) by hydriodic acid reductive hydrolysis of pheomelanin, respectively. Final results were determined by a conversion as described 35 (eumelanin = 45 × PTCA, peomelanin = 9 × 4-AHP). All results are calculated by three independent experiments.
Clonogenic survival and soft agar assays. The clonogenic survival and soft agar assays for hTERT/p53DD/CDK4(R24C)/BRAF(V600E) melanocytes were performed as described previously 26 . Briefly, for the melanocyte growth promoting withdrawal experiments, hTERT/p53DD/CDK4(R24C) /BRAF(V600E) melanocytes were treated with 20 J m −2 UVB in the presence of 1 μ M α -MSH before plating into 6-well plate at 1,000 cells per well, and then subject to clonogenic survival assays 15 days after UVR. Crystal violet was used to stain colonies. DMEM media was used with 10% FBS and penicillin-streptomycin-glutamine. For soft agar assays, cells (10,000 per well) were seeded in 0.5% low-melting-point agarose in DMEM with 10% FBS, layered onto 0.8% agarose in DMEM/10% FBS. The plates were kept in the cell culture incubator for 30 days after which the colonies > 50 μ m were counted under a light microscope. All results are calculated by three independent experiments. In vivo tumorigenesis assay. In vivo tumorigenesis assay of hTERT/p53DD/ CDK4(R24C)/BRAF(V600E) melanocytes was performed as described previously 26 . Briefly, 3 × 10 6 melanocytes were mixed with Matrigel (1:1) and injected subcutaneously into the flanks of male nude mice. Tumour size was measured every 3 days with a caliper, and the tumour volume was determined. Three weeks after inoculation, the tumours were dissected to measure their weights. Statistical analyses. All quantitative data were presented as the mean ± s.d. or s.e.m. of at least three independent experiments by Student's t-test for between group differences and analysis of variance for comparisons among three or more groups (* P < 0.05, * * P < 0.01, * * * P < 0.001). Data availability. All data that support the findings of this study are available on reasonable request from the corresponding author. The contribution authors declare that all relevant data are included in the paper and its supplementary information files. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
Describe how sample size was determined. All sample size and details are included in the manuscript. This is a tumor development experiment, tumor was diagnosed or not, no statistical analysis is required.
Data exclusions
Describe any data exclusions.
No data were excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replications were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
All samples were randomly allocated into experimental groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were blinded to group allocation during data collection and analysis.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
